Contraceptive efficacy and safety of a low-dose oral contraceptive, (0.03 mg ethinyl oestradiol and 2 mg chlormadinone acetate) Belara®, over three medication cycles

References

• van Heusden A M, Fauser B C. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception 1999; 59: 237–243
   PubMed Web of Science ®Google Scholar
• Benagiano G, Bastianelli C, Farris M. Contraception today. Ann NY Acad Sci 2006; 1092: 1–32
   PubMed Web of Science ®Google Scholar
• van der Does J, Exalto N, Dieben T, Bennink H C. Ovarian activity suppression by two different low-dose triphasic oral contraceptives. Contraception 1995; 52: 357–361
   PubMed Web of Science ®Google Scholar
• van Heusden A M, Fauser B C. Residual ovarian activity during oral steroid contraception. Hum Reprod Update 2002; 8: 345–358
   PubMed Web of Science ®Google Scholar
• Hoogland H J, Skouby S O. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993; 47: 583–590
   PubMed Web of Science ®Google Scholar
• Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996; 51: 188–215
   PubMed Web of Science ®Google Scholar
• Kuhl H. Ideal dose of ethinylestradiol. Extragenital effects of oral contraceptives, M Elstein. The Parthenon Publishing Group, New York 1997; 27–38
   Google Scholar
• Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: Efficacy, tolerability and anti-androgenic properties. Contraception 2003; 67: 305–312
   PubMed Web of Science ®Google Scholar
• Bitzer J. Belara—proven benefits in daily practice. Eur J Contracept Reprod Health Care 2005; 10(Suppl 1)19–25
   PubMedGoogle Scholar
• Spona J, Feichtinger W, Kindermann C, et al. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 2.00 mg dienogest on the hemostatic system. Contraception 1997; 56: 67–75
   PubMed Web of Science ®Google Scholar
• Spona J, Feichtinger W, Kindermann C, et al. Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol. Contraception 1996; 54: 299–304
   PubMed Web of Science ®Google Scholar
• Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 1999; 72: 115–120
   PubMed Web of Science ®Google Scholar
• Hackeloer B J, Robinson H P. Ultrasound examination of the growing ovarian follicle and of the corpus luteum during the normal physiologic menstrual cycle. Geburtshilfe Frauenheilkd 1978; 38: 163–168
   PubMed Web of Science ®Google Scholar
• Wetzels L C, Hoogland H J. Relation between ultrasonographic evidence of ovulation and hormonal parameters: Luteinizing hormone surge and initial progesterone rise. Fertil Steril 1982; 37: 336–341
   PubMed Web of Science ®Google Scholar
• Insler V, Glezerman M, Bernstein D. Diagnosis and treatment of the cervical factor of infertility. Reproduction 1981; 5: 295–300
   Google Scholar
• Insler V, Melmed H, Eichenbrenner I, et al. The cervical score, a simple semiquantative method for monitoring of the menstrual cycle. Int J Gynecol Obstet 1972; 10: 223–228
   Google Scholar
• Worret I, Arp W, Zahradnik H P, et al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203: 38–44
   PubMed Web of Science ®Google Scholar
• Zahradnik H P. Belara—a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea. Eur J Contracept Reprod Health Care 2005; 10(Suppl 1)12–18
   PubMed Web of Science ®Google Scholar
• Zahradnik H P, Goldberg J, Andreas J O. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 1998; 57: 103–109
   PubMed Web of Science ®Google Scholar
• Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Results of a post-marketing surveillance study. Clin Drug Invest 2002; 22: 221–231
   Web of Science ®Google Scholar
• Archer D F, Maheux R, DelConte A, O'Brien F B. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG). Contraception 1997; 55: 139–144
   PubMed Web of Science ®Google Scholar
• Fotherby K. Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel. Contraception 1995; 51: 3–12
   PubMed Web of Science ®Google Scholar